Logo Image
|Videos|July 27, 2020

Can Moderna's COVID 19 Vaccine Generate Lasting Immunity?

Dr. Patrick Soon-Shiong, Chairman and CEO of ImmunityBio, explains why T-cell immunity could be an important metric when evaluating experimental COVID-19 vaccines.

Last week, clinicians were reassured by the publication of long anticipated initial results from COVID-19 adenovirus and messenger RNA vaccine candidates, with trials demonstrating that they appear safe and immunogenic. While there is room for optimism, it is worth asking: what are some of the challenges which the data present?

ImmunityBio CEO and Chairman Patrick Soon-Shiong, MD, spoke with Contagion about the firm's adenovirus vector investigational vaccine against SARS-CoV-2. Dr. Soon-Shiong explains why T-cell immunity could be an important metric when evaluating experimental COVID-19 vaccines.

This is the first part of a joint interview with Dr. Patrick Soon-Shiong and oncologist Dr. Adam Brufsky. Dr. Brufsky has a cancer background, but has entered into research collaborations with infectious disease experts to develop our understanding of SARS-CoV-2 and published theories on the potential role of hyperglycemia in the Journal of Medical Virology.

Related to this article

View more
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Read more
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Read more
Measles Update: October 23, 2026
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Measles Update: October 16, 2026
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
Read more